Maravai 10-Q: Q3 Revenue $45.9M, Gross Margin 35.3%, Cash Down to $73.0M After Debt Paydown
MRVI has more than doubled off its 52-week low of $2.545.
Summary
Maravai's Q3 10-Q confirms $45.9 million of revenue and a swing to positive Adjusted EBITDA, but cash dropped to $73.0 million after paying down debt, and no further high-volume CleanCap COVID orders are expected this year.
Key Events · Earnings and Guidance · MRVI
-
Q3 Revenue $45.9M, Up 10.1%
Revenue rose to $45.9 million from $41.6 million, with TriLink up 11.8% to $28.4 million and Cygnus up 7.5% to $17.5 million.
-
Gross Margin Jumps to 35.3%
Gross profit was $16.2 million versus $5.7 million a year ago as cost of revenue fell 17.6% to $29.7 million on realignment savings; nine-month gross margin was 43.2%.
-
Adjusted EBITDA Turns Positive
Adjusted EBITDA was $5.8 million for Q3 2026 versus $(10.8) million a year ago, and $34.8 million for the nine months versus $(31.7) million.
-
Cash Falls to $73.0M After Debt Paydown
Cash and equivalents dropped from $216.9 million at December 31, 2025 to $73.0 million after $294.2 million of principal repayments, offset by $150.0 million of new term loan borrowings under the June 2, 2026 credit agreement.
Analysis · MRVI · Life Sciences
The Q3 numbers were already public on November 4, but the full 10-Q reveals how much the balance sheet has changed: cash fell to $73.0 million from $216.9 million at year-end 2025 after $294.2 million of debt repayments funded by a new $150.0 million term loan. The real improvement is in margins — gross margin of 35.3% versus 13.6% a year ago and positive Adjusted EBITDA of $5.8 million versus a $10.8 million loss — driven by the completed 25% workforce realignment. Against that, management says no further high-volume CleanCap COVID vaccine orders are expected this year and there are no binding orders for 2027, so the base business has to carry the growth. With $73.0 million of cash and a $30.0 million undrawn revolver, runway is adequate but no longer generous.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MRVI was trading at $6.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $2.55 to $9.42. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.